Goldman Sachs reported on Eli Lilly and Company (NYSE:LLY), bumping its target to $95.00 earlier today
- Updated: September 26, 2016
Goldman Sachs bumped up the target of Eli Lilly and Company (NYSE:LLY) to $95.00 stating a potential upside of 0.19%.
Boasting a price of $79.52, Eli Lilly and Company (NYSE:LLY) traded -2.02% lower on the day. With the last close up 3.31% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Eli Lilly and Company has recorded a 50-day average of $79.31 and a two hundred day average of $76.97. Volume of trade was up over the average, with 4,339,140 shares of LLY changing hands over the typical 3,603,540
With a market capitalization of $0, Eli Lilly and Company has 52 week low of $67.88 and a 52 week high of $88.48 with a PE ratio of 34.28 .
In addition to Goldman Sachs reporting its stock price target, a total of 21 brokerages have issued a ratings update on the company. The average stock price target is $95.86 with 7 brokerages rating the stock a strong buy, 9 brokerages rating the stock a buy, 6 brokerages rating the stock a hold, 1 brokerage rating the stock a underperform, and finally 0 brokerages rating the stock a sell.
Brief Synopsis On Eli Lilly and Company (NYSE:LLY)
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company's Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, such as Humalog and Humalog Mix 75/25; neuroscience products, such as Cymbalta and Zyprexa; oncology products, such as Alimta and Cyramza, and cardiovascular products, such as Cialis and ReoPro. The Company's animal health products segment includes products for food animals, such as Rumensin and Posilac; products for companion animals, such as Onsior and Osurnia, and Novartis Animal Health (Novartis AH) products.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.